This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Spine consultant and clinical advisor Mr Nick Birch appointed as NED at OrthoSon

Spine consultant and clinical advisor Mr Nick Birch appointed as NED at OrthoSon

21 Mar 2022

Spine consultant and clinical advisor Mr Nick Birch appointed as NED at OrthoSon    Chairing the Clinical Advisory Group to guide clinical development strategy Oxford, UK, March 21 2022 – OrthoSon, which is developing minimally invasive and motion-restoring treatments for low back pain based on ultrasound and in-situ curing hydrogel implants, is pleased to announce the appointment of spine consultant Mr Nick Birch FRCS (Orth) to its Board... Read more

“Vatic COVID-19 Home Spike Test” OTC EUA Submitted to FDA

“Vatic COVID-19 Home Spike Test” OTC EUA Submitted to FDA

16 Mar 2022

“Vatic COVID-19 Home Spike Test” OTC EUA Submitted to FDA Could Be Only Authorized SALIVA Rapid Test; Preferred to Nasal swabs by 4x in user testing OTC Self-Test Detects Virus Via ACE-2 Protein Binding to Trimeric Spike with Mouth Swab MARCH 16, 2022 – Vatic Health Limited (https://www.vatic.health/usa) today announces that it has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA)... Read more

Exscientia & University of Oxford Launch “Xcellomics” Program

Exscientia & University of Oxford Launch “Xcellomics” Program

10 Mar 2022

Exscientia and University of Oxford Launch “Xcellomics” Program to Expedite Early-Stage Academic Research and Translate Novel Biology Into Future Drug Discovery Program open at no-cost to any academic researcher interested in submitting a proposal OXFORD, England–(BUSINESS WIRE)– Exscientia (Nasdaq: EXAI) and the University of Oxford Target Discovery Institute (Oxford TDI) today announced the formation of Xcellomics – a... Read more

Mirobio Continues Expansion of Team With Key Appointments

Mirobio Continues Expansion of Team With Key Appointments

08 Mar 2022

MIROBIO CONTINUES EXPANSION OF EXECUTIVE LEADERSHIP TEAM WITH KEY APPOINTMENTS TO ADVANCE DEVELOPMENT OF CHECKPOINT AGONIST ANTIBODIES FOR AUTOIMMUNE DISEASE Sanjay Keswani, MBBS, FRCP to join company as Chief Medical Officer bringing extensive experience in drug development and life sciences leadership Lynne Murray, Ph.D., MBA appointed as Chief Scientific Officer after leading MiroBio’s R&D efforts since October 2020 Enhanced leadership... Read more

OMass Establishes Scientific Advisory Board – Experts in Biophysical Approaches to Drug Discovery

OMass Establishes Scientific Advisory Board – Experts in Biophysical Approaches to Drug Discovery

08 Mar 2022

Oxford, United Kingdom – 7 March 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the establishment of its scientific advisory board (SAB), comprising of world-renowned experts across biophysical technologies. The Company’s newly formed SAB will guide OMass’ mission of improving... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More